Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGIN: YOUNG 1
NL-OMON37499Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing Insulin degludec + insulin aspart with Insulin detemir + insulin aspart (2 arms). Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment. Started Feb 2012; status: active, not recruiting.
02
Drugs
insulin degludecinsulin detemirinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON37499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37499.